Cardiovascular Diabetology

, 17:53 | Cite as

Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes

  • Xiao-min Chen
  • Wen-qiang Zhang
  • Yuan Tian
  • Li-fen Wang
  • Chan-chan Chen
  • Chuan-mei Qiu
Open Access
Original investigation
  • 161 Downloads

Abstract

Background

It has been suggested that liraglutide could have an impact on glucose and lipid metabolism disorder and adhesion molecule activation, which may play important roles in the vascular damage of diabetes. In this study, we examined the effects of liraglutide versus metformin on non-esterified free fatty acids, beta-cell insulin secretion, and adhesion molecule levels in patients with recent-onset type 2 diabetes mellitus.

Methods

In this study, 60 patients newly diagnosed with type 2 diabetes mellitus (mean age 33.97 ± 5.67 years) were randomly assigned to receive once-daily subcutaneous liraglutide or oral metformin. Before the study and after the 8-week treatment period, a 75 g oral glucose tolerance test was performed. Plasma glucose, lipids and lipoprotein, plasma insulin, glycaemic and insulin responses, non-esterified free fatty acids (NEFA), and soluble vascular cell adhesion molecule-1 (sVCAM-1) levels were evaluated.

Results

After 8 weeks, 120 min of NEFA (155 ± 125 vs 99 ± 73 µmol/L, P = 0.026) and the levels of sVCAM-1 (465 ± 136 vs 382 ± 131 ng/ml, P = 0.013) significantly decreased, while the early phase insulin secretion index (24.94 [7.78, 38.89] vs. 31.13 [17.67, 59.09], P = 0.031), fasting plasma insulin (104 [51, 123] vs 113 [54, 171] mIU/L, P = 0.015), 60 min plasma insulin (326 [165, 441] vs 471 [334, 717] mIU/L, P = 0.005), 120 min plasma insulin (401 [193, 560] vs 500 [367, 960] mIU/L, P = 0.047), and insulin area under the curve (AUCins) (648 [321, 742] vs 738 [451, 1118] mIU/L, P = 0.005) remarkably increased for patients in the liraglutide treatment group. The levels of sVCAM-1 dramatically decreased after 8 weeks of liraglutide treatment (503 ± 182 vs 382 ± 131 ng/ml, P = 0.046) compared to that of the metformin treatment group. At the same time, the differences before and after liraglutide treatment in 120 min of NEFA (− 32 [− 96, − 5] vs 5 [− 35, 38] µmol/L, P = 0.033) and AUCins (738 [451, 1118] vs 594 [357, 1216] mIU/L, P = 0.014) were remarkably enhanced compared to that of the metformin therapy. Nevertheless, there were no significant differences in fasting NEFA after liraglutide or metformin treatment. The reduction of 120 min NEFA (ΔNEFA) was positively correlated with the decrease of sVCAM-1 (ΔsVCAM-1) after 8 weeks of liraglutide treatment (r = 0.523, P = 0.003).

Conclusions

Our results demonstrate that liraglutide administration is more effective than metformin in reducing 120 min NEFA and suppressing sVCAM-1 levels for recent-onset type 2 diabetes mellitus. We suggest that this outcome may be because liraglutide is associated with potentiating insulin secretion capacity, inhibiting vascular inflammatory cytokines, and antagonizing atherosclerosis.

Keywords

Liraglutide Metformin NEFA sVCAM-1 Type 2 diabetes 

Abbreviations

BMI

body mass index

WC

waist circumference

TC

total cholesterol

TG

triglycerides

HDL-C

high-density lipoprotein cholesterol

LDL-C

low-density lipoprotein cholesterol

Apo

apolipoprotein

FPG

fasting plasma glucose

HbA1c

glycated haemoglobin

SBP

systolic blood pressure

DBP

diastolic blood pressure

OGTT

oral glucose tolerance test

GLP-1

glucagon-like peptide-1

LRG

liraglutide

MET

metformin

NEFA

non-esterified fatty acids

sVCAM-1

soluble vascular cell adhesion molecule-1

sICAM-1

soluble intercellular adhesion molecule-1

PAI-1

plasminogen activator inhibitors-1

ELISA

enzyme-linked immunosorbent assay

HPLC

high performance liquid chromatography

ECLI

electrochemiluminescence immunoassay

CV

coefficients of variation

ROS

reactive oxygen species

GDM

gestational diabetes mellitus

HAECs

human aortic endothelial cells

AMP

activated protein kinase

AMPK

adenosine monophosphate activated protein kinase

CAMKKb

calmodulin dependent protein kinase kinase-b

TNF-α

tumor necrosis factor-α

LPS

lipopolysaccharide

HUVEC

human umbilical vein endothelial cells

MAPK

mitogen-activated protein kinase

NF-kB

nuclear factor kappa-light-chain-enhancer of activated B cells

EMV

endothelial microvesicle

Introduction

It has been well documented that atherosclerosis is the major cause of death in type 2 diabetic patients [1, 2]. Dyslipidaemia plays an important role in the pathogenesis of atherosclerosis and even to insulin resistance [3, 4]. Dyslipidaemia is associated with increased lipolysis and the release of higher amounts non-esterified fatty acids (NEFAs) into the bloodstream [5]. Hyperglycaemia promotes lipolysis and leads to chronic exposure to NEFA [6]. Several studies have shown that the elevated serum level of NEFA contributes to vascular damage in diabetes [7, 8].

Plasma NEFAs promote a systemic insulin resistance state and are correlated with inflammation in atheromatous plaques [5, 7]. The levels of NEFAs seem to be modified by dietary or therapeutic intervention. Glucagon-like peptide-1 (GLP-1) has recently received attention as a novel drug in the antidiabetic field [9]. The long-acting GLP-1 analogue liraglutide (LRG) exhibits pleiotropic effects on glucolipid metabolism, β-cell insulin secretion and anti-atherosclerosis [10, 11, 12, 13, 14, 15]. Nevertheless, the precise mechanism by which liraglutide modulates lipids metabolism remains unclear.

Therefore, the aim of this study is to evaluate whether liraglutide could be more effective at suppressing lipolysis, ameliorating glucose and lipid metabolism, enhancing beta-cell functions, and inhibiting vascular inflammatory markers compared to metformin in recent-onset type 2 diabetes mellitus.

Subjects and methods

Ethical approval

Ethical approval was granted by the Institutional Review Board of Xiamen University Affiliated Zhongshan Hospital according to Helsinki Declaration II. Written informed consent was signed by and obtained from each participant.

Participants

Participants were recruited between October 2015 and December 2016 at Zhongshan Hospital Xiamen University in P. R. China. The inclusion criteria were set to select participants: the patients had an initial diagnosis of type 2 diabetes mellitus who met the World Health Organization criteria for type 2 diabetes and were aged 18–40 years, with a body mass index (BMI) of 25–35 kg/m2, HbA1c of 6.5–9%, and fasting serum triglycerides of 0.5–5 mmol/L. Main exclusion criteria included the following: type 1 diabetes, recent acute complications including diabetic ketoacidosis and hyperglycaemic hyperosmolar state, impaired liver function, impaired renal function (creatinine clearance < 60 ml/min) [16], pregnancy and breast bleeding, and other factors that affect glucose and lipid changes.

Study design and procedures

This study is a randomized, parallel, active comparator trial in 60 participants. The treatment order of liraglutide or metformin was determined through random assignment (1:1). All individuals who received liraglutide treatment started injection doses at 0.6 mg/day. After 1 week of injection, the dose was increased to 1.2 mg/day. Participants in another group who received metformin received an oral dose in the range of 1–2 g/day. After an overnight fast, a 75 g oral glucose tolerance test (OGTT) was conducted for each participant. Blood samples were drawn before and 30, 60, 120 min after OGTT, respectively. Participants in the liraglutide treatment group were instructed to administer the Flexpen device. Participants were also informed of medication precautions before metformin treatment. All participants received lifestyle intervention health education from professional nurse. The total planned treatment period was 8 weeks. There were a total of 3 follow-up visits, once per month. The plasma glucose, blood pressure, body weight, waist circumference and hip circumference were measured, and adverse events were monitored by investigators. At the end of the trial, the clinical and laboratory indices were assessed, as previously described.

Clinical measurement and laboratory test

Weight, waist circumference (WC), and hip circumference were measured by professional nurses. Participants removed clothing and shoes prior to measurements. WC was measured midway between the lowest rib and the top of the iliac crest. Hip circumference was measured around the peak of the buttocks. Body mass index (BMI) was calculated as the body weight (BW) in kilograms divided by the square of the patient’s height in metres. Measurements of systolic blood pressure and diastolic blood pressure (SBP and DBP) were performed 2 times with a mercury manometer on the right arm after 5 min in the sitting position. The mean values of measurements were recorded.

Participants were instructed to refrain from excessive physical exercise and to eat normally 3 days before the test, with no less than 200 grams of carbohydrates daily. After fasting overnight (8–10 h), a 2-h OGTT test was performed on each subject. Fasting plasma glucose (FPG), 30 min PG, 60 min PG, and 120 min PG were measured by the hexokinase method. Subjects’ renal and liver functions, plasma lipids and lipoprotein concentrations including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were assayed using standard methods (Roche cobas8000 automatic biochemical analyser). HbA1c was analysed by HPLC (Bio-Rad, Inc., Hercules, CA, USA). Plasma insulin levels were measured using the electrochemiluminescence immunoassay (ECLI). NEFA levels were measured in the Xiamen Diabetes Hospital using Abbott c16000 automatic biochemical analyser. Soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1) were measured in the plasma of patients using quantikine ELISA kits (R&D systems, Inc., Minneapolis, USA). Plasminogen activator inhibitor 1 (PAI-1) concentrations were assessed using ELISA assays (Multi sciences, Inc., Hangzhou, PRC). The intra-assay and inter-assay coefficients of variation (CV) of the ELISA kits mentioned above were all less than 10%. The early phase insulin secretion index was calculated as (ΔI30/ΔG30) = ([insulin at 30 min] − [insulin at 0 min])/([glucose at 30 min] − [glucose at 0 min]) [17]. The area under the curve (AUC) for plasma insulin during the OGTT was calculated using the trapezoidal rule [18]. Deltas (Δ) are presented as the difference before and after treatment, which were available for the variables ΔNEFA, ΔsVCAM-1, ΔAUCins, and ΔI30/ΔG30. Deltas were also considered to express the difference between 120 min values and fasting values in ΔTC and ΔLDL-C.

Statistical analysis

SPSS version 21 (SPSS software, IBM Inc., USA) and GraphPad Prism version 5.0 (GraphPad software, Inc., La Jolla, CA, USA) were utilized for statistical analysis and the construction of graphs. The normal distribution data are presented as the mean ± standard deviation. Comparisons of basic characteristics between groups were made using an unpaired t test. Comparisons of baseline and post-treatment data in the same group were made using a paired t test. The skewed distribution variables are expressed as the median (interquartile rang), and the Mann–Whitney U test or Wilcoxon signed rank test was performed. The Mann–Whitney U test was used to determine the differences from baseline with a final measurement at 8 weeks for 120 min NEFA, insulin secretion capacity including fasting insulin, 30 min insulin, 60 min insulin, 120 min insulin, ΔI30/ΔG30, and AUCins between the liraglutide and metformin group. At the same time, the Mann–Whitney U test was carried out to determine the differences between 120 min values and fasting values on TC and LDL-C in the metformin group. Spearman rank correlations were performed to determine the relationship of ΔNEFA with ΔsVCAM-1, ΔAUCins and ΔI30/ΔG30 after 8 weeks of treatment. The Chi squared (χ 2 ) test was used for categorical variables. Two-tailed significance was set at P < 0.05.

Results

Comparisons of clinical and laboratory characteristics of the study participants

The patient characteristics grouped by either liraglutide or metformin treatment are presented in Table 1. In the baseline analysis, the differences in participants’ age, BW, BMI, SBP, DBP, WC and hip circumference between the two groups were not statistically significant. HbA1c, FPG, 60 min PG, 120 min PG, NEFA, lipids and lipoprotein concentrations (including TC, TG, LDL-C, HDL-C), insulin secretion capacity, sVCAM-1, sICAM-1, and PAI-1 were similar between the two groups, but 30 min PG was higher at baseline in the liraglutide treatment group.
Table 1

Baseline characteristics of the study participants

Variable

Liraglutide (n = 30)

Metformin (n = 30)

P-value

Age (years)

32.67 ± 5.46

35.27 ± 5.85

0.219

Male/female (n)

20/10

20/10

1.000

BW (kg)

81 ± 17

72 ± 11

0.104

BMI (kg/m2)

28.63 ± 3.86

26.16 ± 3.1

0.063

Waist circumference (cm)

92.20 ± 11.99

88.27 ± 8.22

0.304

Hip circumference (cm)

99.87 ± 6.02

96.33 ± 5.77

0.112

SBP (mmHg)

122 ± 16

120 ± 11

0.643

DBP (mmHg)

79 ± 12

81 ± 7

0.719

Cholesterol (mmol/L)

 Fasting value

4.79 ± 0.87

5.02 ± 0.79

0.444

 120 min value

4.45 ± 1.02

4.55 ± 0.81

0.777

Triglycerides (mmol/L)

 Fasting value

1.82 ± 0.74

1.99 ± 0.74

0.539

 120 min value

2.07 ± 1.23

1.97 ± 0.68

0.802

LDL-C (mmol/L)

 Fasting value

3.61 ± 0.82

3.78 ± 0.68

0.535

 120 min value

3.16 ± 0.70

3.28 ± 0.70

0.639

HDL-C (mmol/L)

 Fasting value

1.12 ± 0.29

1.20 ± 0.26

0.448

 120 min value

1.04 ± 0.35

1.07 ± 0.23

0.793

 HbA1c (%)

8.49 ± 1.81

7.77 ± 1.44

0.238

 FPG (mmol/L)

9.40 ± 2.32

8.45 ± 1.57

0.198

 30 min PG (mmol/L)

15.43 ± 2.96

13.03 ± 2.72

0.028

 60 min PG (mmol/L)

18.19 ± 3.60

16.43 ± 4.13

0.224

 120 min PG (mmol/L)

17.68 ± 4.38

14.47 ± 5.05

0.074

 Fasting insulin (mIU/L)

104 (51, 123)

76 (60, 150)

0.724

 30 min insulin (mIU/L)

271 (136, 298)

211 (118, 444)

0.917

 60 min insulin (mIU/L)

326 (165, 441)

368 (242, 731)

0.152

 120 min insulin (mIU/L)

401 (193, 560)

475 (286, 1060)

0.178

 AUCins (mIU/L)

648 (321, 742)

615 (381, 1167)

0.520

 ΔI30/ΔG30

24.94 (7.78, 38.89)

30.18 (10.4, 53.75)

0.272

NEFA (μmol/L)

 Fasting value

620 ± 468

485 ± 225

0.325

 120 min value

155 ± 125

101 ± 53

0.309

 sVCAM-1 (ng/ml)

465 ± 136

485 ± 122

0.669

 sICAM-1 (ng/ml)

113 ± 40

168 ± 110

0.085

 PAI-1 (ng/ml)

69.52  ± 45.75

51.34  ± 38.87

0.227

Data are expressed as mean ± standard deviation or median (interquartile rang)

BW body weight, BMI body mass index, SBP systolic blood pressure, DBP diatolic blood pressure, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HbA 1 c glycated haemoglobin, FPG fasting plasma glucose, AUCins insulin area under the curve, NEFA non-esterified fatty acids, sVCAM-1 soluble vascular cell adhesion molecule-1, sICAM-1 soluble intercellular adhesion molecule-1, PAI-1 plasminogen activator inhibitors-1

After 8-week metformin treatment, fasting total cholesterol (TC) and low density lipoprotein cholesterin (LDL-C) were remarkably lower compared to baseline (5.02 ± 0.79 vs 4.45 ± 0.28 mmol/L, P = 0.006), (3.78 ± 0.68 vs 3.18 ± 0.88 mmol/L, P = 0.012). At the same time, metformin therapy also reduced 120 min TC (4.55 ± 0.81 vs 4.10 ± 1.21 mmol/L, P = 0.036) and 120 min LDL-C (3.28 ± 0.7 vs 2.76 ± 0.91 mmol/L, P = 0.008) after OGTT. However, in the present study, there were no significant differences between 120 min values and fasting values in ΔTC and ΔLDL-C with respect to metformin treatment. Furthermore, no significant differences were found in plasma lipids and lipoprotein after liraglutide treatment compared with the basal values (shown in Additional file 1: Table S1).

We found a significant reduction in waist circumference (92 ± 12 vs 88 ± 11 cm, P = 0.001) and body weight (81 ± 17 vs 78 ± 16 kg, P = 0.001), as well as BMI (28.63 ± 3.86 vs 27.67 ± 3.62 kg/m2, P = 0.001), with liraglutide treatment. Metformin treatment also showed a slight downtrend in BW and BMI, although the difference was not significant (shown in Additional file 1: Table S2).

Liraglutide treatment elevated insulin secretion capacity and decreased plasma glucose

Early phase insulin secretion index (ΔI30/ΔG30) (24.94 [7.78, 38.89] vs 31.13 [17.67, 59.09], P = 0.031), fast plasma insulin (104 [51, 123] vs 113 [54, 171] mIU/L, P = 0.015), 60 min plasma insulin (326 [165, 441] vs 471 [334, 717] mIU/L, P = 0.005), 120 min plasma insulin (401 [193, 560] vs 500 [367, 960] mIU/L, P = 0.047), and insulin area under the curve (AUCins) (648 [321, 742] vs 738 [451, 1118] mIU/L, P = 0.005) significantly increased with liraglutide treatment. The differences in AUCins (ΔAUCins) before and after liraglutide treatment (738 [451, 1118] vs 594 [357, 1216] mIU/L, P = 0.014) were remarkably enhanced compared to that in metformin therapy, but differences in ΔI30/ΔG30 before and after liraglutide treatment (6.01 [1.79, 28.46] vs − 2.62 [− 14.85, 8.76], P = 0.065) were not significant between the two groups (Table 2). In fact, both liraglutide (8.49 ± 1.81 vs 6.92 ± 0.81%, P = 0.002) and metformin treatment (7.77 ± 1.44 vs 6.43 ± 0.71%, P = 0.001) could reduce HbA1c values. FPG, 30 min PG, 60 min PG and 120 min PG all decreased after liraglutide treatment, but only FPG was significantly reduced after metformin treatment (shown in Additional file 1: Table S2).
Table 2

Comparisons of sVCAM-1, 120 min NEFA, AUCins and ΔI30/ΔG30 levels after 8-week treatment between liraglutide and metformin group

Variable

Liraglutide

Metformin

Difference

P-value

sVCAM-1 (ng/ml)

382 ± 131

503 ± 182

 

0.046

120 min NEFA (μmol/L)a

− 32 (− 96, − 5)

5 (− 35, 38)

− 20.5 (− 46.5, 31.5)

0.033

AUCins (mIU/L)a

738 (451, 1118)

594 (357, 1216)

39 (− 33, 227)

0.014

ΔI30/ΔG30a

6.01 (1.79, 28.46)

− 2.62 (− 14.85,8.76)

4.56 (− 4.82, 12.99)

0.065

Data are expressed as mean ± standard deviation or median (interquartile rang)

sVCAM-1 soluble vascular cell adhesion molecule-1, NEFA non-esterified fatty acids, AUCins insulin area under the curve

ΔI30/ΔG30 = [(insulin at 30 min) − (insulin at 0 min)]/[(glucose at 30 min) − (glucose at 0 min)]

aDifference between pre-treatment and post-treatment

Liraglutide treatment inhibited 120 min non-esterified free fatty acids

After 8 weeks, there was a progressive decrease in the levels of 120 min NEFA (155 ± 125 vs 99 ± 73 µmol/L, P = 0.026) after liraglutide treatment. Compared with metformin therapy, the reduction in 120 min NEFA (ΔNEFA) remarkably increased after 8-week liraglutide treatment [− 32 (− 96, − 5) vs 5 (− 35, 38) µmol/L, P = 0.033] (Table 2). The changes in 120 min NEFA showed a slight increase after metformin therapy (Fig. 1). There were no significant changes in fasting non-esterified free fatty acids after liraglutide and metformin treatment.
Fig. 1

a 120 min non-esterified fatty acid (NEFA) before and after 8-week treatment with liraglutide and metformin. b The difference of NEFA (∆ NEFA) between baseline and after 8-week treatment with liraglutide and metformin *P <0.05 vs the metformin group

Liraglutide treatment inhibited vascular inflammatory marker levels

We found a significant reduction in sVCAM-1 (465 ± 136 vs 382 ± 131 ng/ml, P = 0.013) after liraglutide treatment compared with baseline. Compared to metformin therapy, the levels of sVCAM-1 were remarkably suppressed after 8-week liraglutide treatment (382 ± 131 vs 503 ± 182 ng/ml, P = 0.046) (Fig. 2, Table 2). However, there were no significant differences in sICAM-1 and PAI-1 levels before and after liraglutide and metformin therapy (shown in Additional file 1: Table S3). In all subjects combined, the reduction of 120 min NEFA (ΔNEFA) was positively correlated with the decrease of sVCAM-1 (ΔsVCAM-1) after 8-week liraglutide treatment (r = 0.523, P = 0.003), which was not significantly negatively correlated with the increase of AUCins (ΔAUCins) (r = − 0.286, P = 0.125) and ΔI30/ΔG30 (r = − 0.150, P = 0.429) (shown in Additional file 1: Table S4).
Fig. 2

Changes of soluble vascular cell adhesion molecule-1 (sVCAM-1) before and after 8-week treatment with liraglutide and metformin

Discussion

Our results indicate that prolonged liraglutide treatment for 8 weeks effectively inhibited 120 min non-esterified free fatty acids (NEFAs). We utilized a 75 g oral glucose tolerance test (OGTT) to evaluate the changes of NEFA, which should avoid the effects of a high-fat diet on postprandial lipid metabolism. As observed in this study, NEFA levels gradually decreased after glucose uptake, and 120 min NEFAs are dramatically lower than fasting NEFAs. Furthermore, our data show that liraglutide exhibits greater stimulation on the insulin secretion capacity, including early phase insulin secretion, fast plasma insulin, 60 min plasma insulin, 120 min plasma insulin and insulin area under the curve (AUCins) relative to those at baseline. Previous research has shown that insulin could suppress chylomicron synthesis from human jejunal explants [19]. Additionally, circulating FFAs derived from chylomicron are reduced in the hyperinsulinaemia state, as insulin prevents lipolysis in the regulation of hepatic and intestinal lipoprotein production [20, 21].

Our data demonstrated that after the 8-week treatment period, the reduction in 120 min NEFA (ΔNEFA) was greater increased, and the increase in AUCins (ΔAUCins) was also enhanced in liraglutide treatment relative to metformin treatment. Consequently, in this study, liraglutide therapy exhibited beneficial effects in ameliorating the β-cell secretion capacity and suppressing free fatty acid production. However, the precise mechanisms by which glucagon-like peptide-1 affects lipids metabolism are less certain. It has been hypothesized that enterocyte GLP-1 receptor signalling is essential for postprandial lipoprotein synthesis and secretion, reduces intestinal lipid production and absorption, and prevents the postprandial increases in triacylglycerol, cholesterol and apo-B48 levels [22]. Moreover, GLP-1 is related to the direct modulation of fatty acid binding protein 2 (FABP2), which is required for the formation of apo-B48 containing chylomicrons [23]. In addition, even through enhanced insulin secretion, GLP-1 induced prolonged reductions in NEFA concentrations after meals, suppressed postprandial rises in ApoCIII [24]. ApoCIII is a small glycoprotein synthesized in the liver and intestine that resides predominantly on the surface of ApoB-containing lipoproteins and HDL. ApoCIII inhibits lipoprotein lipase activity and interferes with the receptor-mediated uptake of TG-rich lipoproteins, therefore delaying the clearance of TG-rich lipoproteins [25, 26]. On the other hand, a long-term increase in NEFA levels has been associated with ROS accumulation, which causes mitochondrial stress and leads to β-cell apoptosis [27, 28]. In a catch-up growth rat model by re-feeding with high-fat diet, liraglutide prevented the increase of plasma NEFA, increased insulin secretion, increased islet pancreatic duodenal homeobox-1 (Pdx-1) and B cell lymphoma-2 (Bcl-2) expression, and reduced procaspase-3 transcription and Caspase-3 p11 subunit protein expression, which suggested that liraglutide treatment could antagonize β-cell apoptosis caused by elevated NEFA [11].

Dyslipidaemia has been reported to affect vascular endothelial function by the inflammatory pathway [29]. Raised non-esterified fatty acids impair insulin’s effect on glucose uptake in skeletal muscle and could thus have detrimental effects on the vascular endothelium, which leads to premature cardiovascular disease [30]. As reported previously, the adhesion molecules usually act as biomarkers, which mediate interactions between leukocytes and the vascular endothelium, shed from cell surfaces and become soluble isoforms in the blood, namely, sVCAM-1 and sICAM-1 [31]. Our study has shown that the levels of the vascular inflammatory marker sVCAM-1 are dramatically suppressed after liraglutide treatment compared to metformin treatment. However, we did not identify appreciable differences in the levels of sICAM-1 and PAI-1 after liraglutide therapy.

Considerable evidence has demonstrated that sVCAM-1 plays an important role in the pathophysiological mechanisms of atherosclerosis [32]. During a 10-year follow-up, a longitudinal study revealed that elevated circulating sVCAM-1 concentrations in females with a history of gestational diabetes mellitus (GDM) not only represented the earliest high risk stage for developing type 2 diabetes, but also reflected the early stage of the pathway for the manifestation of future cardiometabolic disorders [33]. It is widely known that atherosclerosis leads to macroangiopathy and is responsible for most deaths in patients with diabetes [34]. Liraglutide was shown to significantly reduce the risk of major cardiovascular events in the large prospective LEADER trial [12, 35, 36, 37]. However, the precise mechanisms behind the antiatherogenic effect of liraglutide are not entirely clear, although several hypotheses have been proposed. First, it has been shown that in cultured human aortic endothelial cells (HAECs), liraglutide reduces the protein expression of VCAM-1 in response to TNFα and LPS stimulation and increases intracellular calcium and cAMP levels, leading to the phosphorylation of AMPK, which is an evolutionarily conserved fuel and stress-sensing enzyme that can be activated by calmodulin dependent protein kinase kinase-b (CAMKKb), and then downregulates monocyte adhesion, which presumably inhibits atherogenesis [38, 39]. Second, in a cellular model of human umbilical vein endothelial cells (HUVECs) obtained from umbilical cords of women affected by GDM, liraglutide exposure significantly mitigated TNFα induced endothelial monocyte adhesion as well as VCAM-1 and ICAM-1 expression, reduced the phosphorylation of the MAPK42/44 signalling pathway, inhibited NF-kB p65 nuclear translocation, and decreased peroxynitrite levels and endothelial microvesicle (EMV) release [40]. Third, after 8-week metformin treatment, TC and LDL-C were remarkably lower compared to baseline, but no significant differences were found between 120 min values and fasting values in ΔTC and ΔLDL-C. Moreover, no significant differences were found in plasma TC and LDL-C after liraglutide treatment. We presumed that liraglutide exert antiatherogenic mechanism, which might be not related to a decrease of LDL-C levels but might be related to an enhancement of HDL anti-inflammatory capacity [41].

We carried out a Spearman rank correlation assay and the data showed that the reduction of 120 min NEFA (ΔNEFA) was positively correlated with the decrease of sVCAM-1 (ΔsVCAM-1) after 8-week liraglutide treatment. Our results suggest that liraglutide has beneficial effects on suppressing plasma NEFA as well as sVCAM-1 levels, which is likely to indicate that liraglutide could protect the endothelia by inhibiting monocyte cell adhesion and sVCAM-1 activation and reducing lipocyte oxidative stress and free fatty acid production, revealing an antiatherogenic effects [42, 43].

The strengths of this study include the randomized, parallel, active comparator design and the similarities between the liraglutide and metformin groups at baseline. To the best of our knowledge, this is the first study to verify that liraglutide treatment is more effective than metformin treatment for recent-onset type 2 diabetes mellitus in reducing NEFA after glucose intake and suppressing sVCAM-1 levels at the same time. However, this study has certain limitations. First, it has a non-blinded design, lacks a non-treatment control group, and has a small sample size for the study. Second, further studies are needed to reveal the relevant signalling pathways by which liraglutide might influence glucose and lipid metabolism, regulate vascular endothelial function, and antagonize atherosclerosis.

Conclusions

In brief, this study demonstrated that liraglutide administration is more effective in diminishing 120 min NEFAs and suppressing sVCAM-1 levels than metformin in young patients with recent-onset type 2 diabetes mellitus. This outcome could be associated with potentiating insulin secretion capacity and antagonizing vascular inflammatory cytokines. Therefore, these results suggest that liraglutide may exert a protective effect on alleviating vascular damage, antagonizing atherosclerosis, and reducing the risk of cardiovascular disease in the course of type 2 diabetes.

Notes

Authors’ contributions.

XC conceived and designed the research. XC, LW, WZ, YT, CC and CQ performed the experiments. XC and WZ analysed the data. XC drafted the manuscript. All authors contributed to the writing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank all the research subjects for their participation and acknowledge the skillful work of the entire medical staff at the Department of Endocrinology and Metabolism, Zhongshan Hospital Xiamen University. We are very grateful to Shaojie Wang (Nanolab Technologies, Milpitas, California, USA) for the language polishing, Yin-xiang Huang (Xiamen Diabetes Hospital, Xiamen, P. R. China) for the NEFA measurement, Yu-bing Yan (Zhongshan Hospital Xiamen University, Xiamen, P. R. China) for the statistical analysis.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its additional files.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Ethical approval was granted by the Institutional Review Board of Xiamen University Zhongshan Hospital according to Helsinki Declaration II. All subjects provided written informed consent to participate.

Funding

This work was financially supported by the Science and Technology Benefit Fund of Xiamen Technology Bureau (3502Z20154027).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary material

12933_2018_701_MOESM1_ESM.zip (33 kb)
Additional file 1: Table S1. Changes of plasma lipids and lipoprotein metabolism parameters before and after 8-week treatment with liraglutide and metfotmin. Table S2. Comparisons of body weight, plasma glucose and insulin secretion capacity before and after 8-week treatment between two groups. Table S3. Comparisons of sVCAM-1,sICAM-1,PAI-1 levels before and after 8-week treatment between two groups. Table S4. Spearman rank correlations in ΔNEFA with ΔsVCAM-1, ΔAUCins and ΔI30/ΔG30 after 8-week treatment.

References

  1. 1.
    Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434–44.CrossRefPubMedGoogle Scholar
  3. 3.
    Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA. Lipid mediators of insulin resistance. Nutr Rev. 2007;65:S39–46.CrossRefPubMedGoogle Scholar
  4. 4.
    Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010;375:2267–77.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep. 2006;6:177–81.CrossRefPubMedGoogle Scholar
  6. 6.
    Wilding JP. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med. 2007;24:934–45.CrossRefPubMedGoogle Scholar
  7. 7.
    Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest. 2006;116(4):1071–80.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Zhou HG, Liu L, Zhang Y, Huang YY, Tao YH, Zhang S, et al. Glutathione prevents free fatty acids-induced oxidative stress and apoptosis in human brain vascular endothelial cells through Akt pathway. CNS Neurosci Ther. 2013;19(4):252–61.CrossRefPubMedGoogle Scholar
  9. 9.
    Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014;34(11):1174–86.CrossRefPubMedGoogle Scholar
  10. 10.
    Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care. 2014;37(12):3270–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Zheng J, Chen T, Zhu Y, Li HQ, Deng XL, Wang QH, Zhang JY, Chen LL. Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats. Exp Biol Med (Maywood). 2015;240(9):1165–76.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Masmiquel L, Leiter LA, Vidal J, Bain S, Petrie J, Franek E, et al. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc Diabetol. 2016;15(1):29.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, Mikhailidis DP. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011;13(4):302–12.CrossRefPubMedGoogle Scholar
  14. 14.
    Bruen R, Curley S, Kajani S, Crean D, O’Reilly ME, Lucitt MB, Godson CG, McGillicuddy FC, Belton O. Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis. Cardiovasc Diabetol. 2017;16(1):143.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther. 2014;28(5):425–32.CrossRefPubMedGoogle Scholar
  16. 16.
    Hiramatsu T, Ozeki A, Ishikawa H, Furuta S. Long term effects of liraglutide in japanese patients with type 2 diabetes among the subgroups with different renal functions: results of 2-year prospective study. Drug Res (Stuttg). 2017;67(11):640–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Spadaro L, Alagona C, Palermo F, Piro S, Calanna S, Parrinello G, Purrello F, Rabuazzo AM. Early phase insulin secretion is increased in subjects with normal fasting glucose and metabolic syndrome: a premature feature of beta-cell dysfunction. Nutr Metab Cardiovasc Dis. 2011;21(3):206–12.CrossRefPubMedGoogle Scholar
  18. 18.
    Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer X. The use of areas under curves in diabetes research. Diabetes Care. 1995;18(2):245–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Loirdighi N, Menard D, Levy E. Insulin decreases chylomicron production in human fetal small intestine. Biochim Biophys Acta. 1992;1175:100–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of nonesterified fatty acids in humans. Diabetologia. 2006;49:452–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Pavlic M, Xiao C, Szeto L, Patterson BW, Lewis GF. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes. 2010;59:580–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010;53:552–61.CrossRefPubMedGoogle Scholar
  23. 23.
    Cianflone K, Paglialunga S, Roy C. Intestinally derived lipids: metabolic regulation and consequences–an overview. Atheroscler Suppl. 2008;9:63–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset of type 2 diabetes mellitus. Atherosclerosis. 2010;212:217–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985;75:384–90.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol. 1995;15:963–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia. 2003;46:1297–312.CrossRefPubMedGoogle Scholar
  28. 28.
    Newsholme P, Haber EP, Hirabara SM, Rebelato ELO, Procopio J, Morgan D, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and nonmitochondrial ROS production and activity. J Physiol. 2007;583(1):9–24.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Teng KT, Chang CY, Kanthimathi MS, Tan AT, Nesaretnam K. Effects of amount and type of dietary fats on postprandial lipemia and thrombogenic markers in individuals with metabolic syndrome. Atherosclerosis. 2015;242(1):281–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia. 2002;45(5):623–34.CrossRefPubMedGoogle Scholar
  31. 31.
    Zonneveld R, Martinelli R, Shapiro NI, Kuijpers TW, Plotz FB, Carman CV. Soluble adhesion molecules as markers for sepsis and the potential pathophysiological discrepancy in neonates, children and adults. Crit Care. 2014;18:204.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    van Eupen MG, Schram MT, Colhoun HM, Hanssen NM, Niessen HW, Tarnow L, et al. The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. Diabetologia. 2013;56(8):1845–55.CrossRefPubMedGoogle Scholar
  33. 33.
    Göbl CS, Bozkurt L, Yarragudi R, Prikoszovich T, Tura A, Pacini G, Koppensteiner R, Kautzky-Willer A. A Biomarkers of endothelial dysfunction in relation to impaired carbohydrate metabolism following pregnancy with gestational diabetes mellitus. Cardiovasc Diabetol. 2014;13:138.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–81.CrossRefPubMedGoogle Scholar
  35. 35.
    Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, et al. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016;15(1):162.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Vergès B, Charbonnel B. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? Diabetes Metab. 2017;43(Suppl 1):S3–12.Google Scholar
  38. 38.
    Hawley S, Selbert M, Goldstein E, Edelman A, Carling D, et al. 5′-AMP activates the AMP-activated protein kinase cascade, and Ca2 +/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J Biol Chem. 1995;270:27186–91.CrossRefPubMedGoogle Scholar
  39. 39.
    Krasner NM, Ido Y, Ruderman NB, Cacicedo JM. Glucagon-like peptide-1(GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS ONE. 2014;9(5):e9755.CrossRefGoogle Scholar
  40. 40.
    Di Tomo P, Lanuti P, Di Pietro N, Baldassarre MPA, Marchisio M, Pandolfi A, Consoli A, Formoso G. Liraglutide mitigates TNF-α induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women. Diabetes Metab Res Rev. 2017;33:e2925.CrossRefGoogle Scholar
  41. 41.
    Ebtehaj S, Gruppen EG, Parvizi M, Tietge UJF, Dullaart RPF. The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovasc Diabetol. 2017;16(1):132.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209–15.CrossRefPubMedGoogle Scholar
  43. 43.
    Li PC, Liu LF, Jou MJ, Wang HK. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci. 2016;17(1):37.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of Endocrinology and MetabolismZhongshan Hospital Xiamen UniversityXiamenPeople’s Republic of China
  2. 2.Guangzhou Medicine University Second Affiliated HospitalGuangzhouPeople’s Republic of China

Personalised recommendations